Cite
HARVARD Citation
Louis, E. et al. (n.d.). P631 Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn's Disease (CD): Results from a large multinational prospective observational study. Journal of Crohn's and colitis. pp. i762-i763. [Online].